Aprutumab
Aprutumab is an investigational monoclonal antibody (mAb) that is being studied for its potential use in the treatment of certain types of cancer. As a targeted therapy, aprutumab is designed to bind to specific antigens expressed on the surface of cancer cells, thereby inhibiting their growth and survival.
Mechanism of Action[edit | edit source]
Aprutumab functions by targeting a specific antigen that is overexpressed in certain cancer cells. Upon binding to this antigen, aprutumab can induce antibody-dependent cellular cytotoxicity (ADCC), which recruits immune cells to destroy the cancer cells. Additionally, it may block signaling pathways that are essential for tumor growth and proliferation.
Clinical Development[edit | edit source]
Aprutumab is currently undergoing clinical trials to evaluate its safety and efficacy in patients with various types of cancer, including breast cancer, lung cancer, and colorectal cancer. Early-phase trials have shown promising results, with some patients experiencing partial or complete responses.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of aprutumab is characterized by its absorption, distribution, metabolism, and excretion. As a monoclonal antibody, aprutumab is typically administered via intravenous infusion. It has a long half-life, allowing for less frequent dosing compared to small molecule drugs.
Adverse Effects[edit | edit source]
Common adverse effects associated with aprutumab include infusion-related reactions, fatigue, nausea, and mild hematological abnormalities. Serious adverse effects are rare but may include severe allergic reactions and immune-mediated conditions.
Regulatory Status[edit | edit source]
As of the latest update, aprutumab has not yet received approval from major regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It remains an investigational drug, and further studies are needed to confirm its safety and efficacy.
Also see[edit | edit source]
- Monoclonal antibody therapy
- Targeted cancer therapy
- Antibody-dependent cellular cytotoxicity
- Clinical trial phases
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
